CYP2E1 and metabolic dysfunction-associated steatotic liver disease: Finally, the profile of urine caffeine metabolites is sensitive to NAFLD severity, and may serve as a non-invasive marker of hepatic CYP2E1 expression, an important driver of NAFLD progression.